RTP Mobile Logo
Select Publications

Ahn M et al. Osimertinib for patients (pts) with leptomeningeal metastases (LM) associated with EGFRm advanced NSCLC: The AURA LM study. Ann Oncol 2019;30(Suppl 2):ii40. Abstract

Brown PD et al. Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C/CEC. 3): A multicentre, randomised, controlled, phase III trial. Lancet Oncol 2017;18(8):1049-60. Abstract

Brown PD et al. Effect of radiosurgery alone vs radiosurgery with whole brain radiation therapy on cognitive function in patients with 1 to 3 brain metastases: A randomized clinical trial. JAMA 2016;316(4):401-9. Abstract

Brown PD et al. Memantine for the prevention of cognitive dysfunction in patients receiving whole-brain radiotherapy: A randomized, double-blind, placebo-controlled trial. Neuro Oncol 2013;15(10):1429-37. Abstract

Camidge DR et al. Brigatinib versus crizotinib in ALK-positive NSCLC. N Engl J Med 2018;379(21):2027-39. Abstract

Costa DB et al. Clinical experience with crizotinib in patients with advanced ALK-rearranged NSCLC and brain metastases. J Clin Oncol 2015;33(17):1881-8. Abstract

Eisele SC, Dietrich J. Cerebral radiation necrosis: Diagnostic challenge and clinical management. Rev Neurol 2015;61(5):225-32. Abstract

Fan Y et al. EGFR-TKI therapy for patients with brain metastases from NSCLC: A pooled analysis of published data. Onco Targets Ther 2014;7:2075-84. Abstract

Goldberg S et al. Durability of brain metastasis response and overall survival in patients with NSCLC treated with pembrolizumab. Proc ASCO 2018;Abstract 2009.

Goldberg SB et al. Pembrolizumab for patients with melanoma or NSCLC and untreated brain metastases: Early analysis of a nonrandomised, open-label, phase II trial. Lancet Oncol 2016;17(7):976-83. Abstract

Khalifa J et al. Brain metastases from NSCLC: Radiation therapy in the era of targeted therapies. J Thorac Oncol 2016;11(10):1627-43. Abstract

Kim DW et al. Brigatinib in patients with crizotinib-refractory anaplastic lymphoma kinase-positive NSCLC: A randomized, multicenter phase II trial. J Clin Oncol 2017;35(22):2490-8. Abstract

Magnuson WJ et al. Management of brain metastases in tyrosine kinase inhibitor-naïve epidermal growth factor receptor-mutant non-small-cell lung cancer: A retrospective multi-institutional analysis. J Clin Oncol 2017;35(10):1070-7. Abstract

Mehta MP, Ahluwalia MS. Whole-brain radiotherapy and stereotactic radiosurgery in brain metastases: What is the evidence? Am Soc Clin Oncol Educ Book 2015:e99-104. Abstract

Peters S et al. Alectinib versus crizotinib in untreated ALK-positive NSCLC. N Engl J Med 2017;377(9):829-38. Abstract

Rangachari D et al. Brain metastases in patients with EGFR-mutated or ALK-rearranged NSCLCs. Lung Cancer 2015;88(1):108-11. Abstract

Remon J et al. Leptomeningeal carcinomatosis in NSCLC patients: A continuing challenge in the personalized treatment era. Cancer Treat Rev 2017;53:128-37. Abstract

Reungwetwattana T et al. CNS response to osimertinib versus standard epidermal growth factor receptor tyrosine kinase inhibitors in patients with untreated EGFR-mutated advanced non-small-cell lung cancer. J Clin Oncol 2018;36(33):3290-7. Abstract

Schoenfeld AJ et al. Severe immune related adverse events are common with sequential PD-(L)1 blockade and osimertinib. Ann Oncol 2019;30(5):839-44. Abstract

Solomon BJ et al. Lorlatinib in patients with ALK-positive NSCLC: Results from a global Phase II study. Lancet Oncol 2018;19(12):1654-67. Abstract

Sørensen JB et al. Brain metastases in adenocarcinoma of the lung: Frequency, risk groups, and prognosis. J Clin Oncol 1988;6(9):1474-80. Abstract

Soria JC et al; FLAURA Investigators. Osimertinib in untreated EGFR-mutated advanced NSCLC. N Engl J Med 2018;378(2):113-25. Abstract

Soria JC et al. First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged NSCLC (ASCEND-4): A randomised, open-label, Phase III study. Lancet 2017;389(10072):917-29. Abstract

Weiss J et al. Phase II study of stereotactic radiosurgery for the treatment of patients with oligoprogression on erlotinib. Cancer Treat Res Commun 2019;19:100126. Abstract

Wu YL et al. CNS response to osimertinib in patients with T790M-positive advanced NSCLC: Data from a randomized Phase III trial (AURA3). J Clin Oncol 2018;36(26):2702-9. Abstract

Yamamoto M et al. Stereotactic radiosurgery for patients with multiple brain metastases (JLGK0901): A multi-institutional prospective observational study. Lancet Oncol 2014;15(4):387-95. Abstract

Yang JC et al. Osimertinib plus durvalumab versus osimertinib monotherapy in EGFR T790M-positive NSCLC following previous EGFR TKI therapy: CAURAL brief report. J Thoracic Oncol 2019;14(5):933-9. Abstract

Yang JC et al. Pembrolizumab in combination with erlotinib or gefitinib as first-line therapy for advanced NSCLC with sensitizing EGFR mutation. J Thoracic Oncol 2019;14(3):553-9. Abstract

Yang JC et al. Osimertinib for patients with leptomeningeal metastases from EGFR-mutant NSCLC: Updated results from the BLOOM study. Proc ASCO 2017;Abstract 2020.